Critical Contrast: Cocrystal Pharma (NASDAQ:COCP) and Immuneering (NASDAQ:IMRX)

Cocrystal Pharma (NASDAQ:COCP) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Institutional & Insider Ownership

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 22.9% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Cocrystal Pharma and Immuneering’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
Immuneering	N/A	-31.93%	-29.92%

Earnings & Valuation

This table compares Cocrystal Pharma and Immuneering”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83 million	($0.73)	-1.36
Immuneering	N/A	N/A	-$56.03 million	($1.17)	-3.58

Immuneering is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Cocrystal Pharma has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Immuneering has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Cocrystal Pharma and Immuneering, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1	0	1	0	2.00
Immuneering	1	0	5	1	2.86

Cocrystal Pharma currently has a consensus price target of $6.00, suggesting a potential upside of 506.00%. Immuneering has a consensus price target of $16.50, suggesting a potential upside of 293.79%. Given Cocrystal Pharma’s higher probable upside, research analysts plainly believe Cocrystal Pharma is more favorable than Immuneering.

About Cocrystal Pharma

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.